‘Buffer genes’ may protect these 13 people from rare genetic diseases
By Jocelyn Kaiser,
Science/AAAS
| 04. 11. 2016
Untitled Document
A sweeping look at the DNA of more than half-a-million people has uncovered a surprise: A few individuals carry a genetic glitch that should make them very sick, yet they are instead seemingly healthy. Studying such disease-resistant people could point to new treatments for rare conditions like Duchenne muscular dystrophy. But the researchers behind the new survey caution that without direct access to the individuals in the database they used, they have not been able to confirm their results through further testing.
The study is a first step in the Resilience Project, an effort led by Stephen Friend, president of Sage Bionetworks in Seattle, Washington, and genomics researcher Eric Schadt of the Icahn School of Medicine at Mount Sinai in New York City. They want to find healthy individuals who have genetic mutations that usually cause serious disease in those who carry them, such as those for the lung disorder cystic fibrosis. If a person who has such a mutation is well, he or she may carry a mutation in a different gene that compensates for, or buffers, the harmful...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...